Fig. 5From: A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in UgandaForest plot of sensitivity analysis of 3 clinical trials comparing NECT to eflornithine and 1 clinical trial comparing NECT to melarsoprol. (Risk difference, random effects model)Back to article page